Author

S. Boyoglu-Barnum

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 11

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 10 Research Focus:host-pathogen & immune response· 9 Organism:non-human primate· 7 Assay:proteomics· 6 Organism:mouse· 4 Research Focus:drug response / drug discovery· 3 Research Focus:cell type annotation· 2 Organism:human· 2

Frequent Co-Authors

K. S. Corbett· 8 shared B. M. Nagata· 5 shared K. W. Bock· 5 shared M. Kanekiyo· 5 shared M. Minai· 5 shared W. Shi· 5 shared A. Choi· 4 shared A. Cook· 4 shared

Activity by Year

2018-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

8 shared papersImmunology

K. S. Corbett

Mutual co-authors in cluster

Author profile →

11 papers

Recent·Most cited

Antigen spacing on protein nanoparticles influences antibody responses to vaccination

D. Ellis, A. Dosey, S. Boyoglu-Barnum, Y.-J. Park, R. Gillespie, H. Syeda, Y. Tsybovsky, M. Murphy, D. Pettie, N. Matheson, S. Chan, G. Ueda, J. Fallas, L. Carter, B. Graham, , N. P. King

This study shows that antigen spacing on protein nanoparticles affects antibody responses to vaccination, with decreased spacing improving hemagglutination inhibition and neutralization potency.

bioRxiv · May 23, 2023Immunology

Combinatorial immune refocusing within the influenza hemagglutinin head elicits cross-neutralizing antibody responses

A. Dosey, D. Ellis, S. Boyoglu-Barnum, H. Syeda, M. Saunders, M. Watson, J. C. Kraft, M. N. Pham, M. Guttman, K. K. Lee, M. Kanekiyo, N. P. King

This study evaluates trihead nanoparticle immunogens to enhance cross-neutralizing antibody responses against influenza H1 viruses by combining immunofocusing techniques.

bioRxiv · May 23, 2023 · PreprintImmunology

Vaccine-elicitation of cross-group neutralizing protective antibodies to influenza A viruses

S. M. Moin, J. C. Boyington, S. Boyoglu-Barnum, R. A. Gillespie, G. Cerutti, C. S.-F. Cheung, A. Cagigi, J. R. Gallagher, J. Brand, M. Prabhakaran, Y. Tsybovsky, T. Stephens, B. E. Fisher, A. Creanga, S. Ataca, , M. Kanekiyo

This study shows that co-immunization with stem immunogens from group 1 and 2 influenza A HAs elicits cross-group neutralizing antibodies and protective immunity in multiple animal models.

bioRxiv · Feb 11, 2022 · PreprintImmunology

Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway

M. Gagne, K. S. Corbett, B. J. Flynn, K. E. Foulds, D. A. Wagner, S. F. Andrew, J.-P. M. Todd, C. C. Honeycutt, L. McCormick, S. T. Nurmukhambetova, M. E. Davis-Gardner, L. Pessaint, K. W. Bock, B. M. Nagata, M. Minai, , B. S. Graham

This study shows that mRNA-1273 vaccine protection against SARS-CoV-2 Delta in nonhuman primates persists for one year but is delayed and relies on anamnestic antibody responses in the lower airway.

bioRxiv · Oct 23, 2021 · PreprintImmunology

Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates

K. S. Corbett, M. Gagne, D. Wagner, S. O'Connell, S. R. Narpala, D. R. Flebbe, S. F. Andrew, R. L. Davis, B. Flynn, T. S. Johnston, C. Stringham, L. Lai, D. Valentin, A. Van Ry, Z. Flinchbaugh, , A Pekosz

mRNA-1273 boosted nonhuman primates show increased neutralizing antibody responses and protection against SARS-CoV-2 beta variant infection.

bioRxiv · Aug 11, 2021 · PreprintImmunology

Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates

K. S. Corbett, A. Werner, S. O'Connell, M. Gagne, L. Lai, J. Moliva, B. Flynn, A. Choi, M. Koch, K. E. Foulds, S. Andrew, D. Flebbe, E. Lamb, S. T. Nurmukhambetova, S. Provost, , M. Suthar

This study evaluates mRNA-1273 vaccine efficacy against SARS-CoV-2 B.1.351 in nonhuman primates, finding that two doses significantly reduce viral replication in the airways.

bioRxiv · May 21, 2021 · PreprintImmunology

Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates

K. S. Corbett, M. C. Nason, B. Flach, M. Gagne, S. O'Connell, T. S. Johnston, S. N. Shah, V. V. Edara, K. Floyd, L. Lai, C. McDanal, J. R. Francica, B. Flynn, K. Wu, A. Choi, , Leung

This study shows that mRNA-1273 vaccine-induced antibody responses correlate with protection against SARS-CoV-2 infection in nonhuman primates.

bioRxiv · Apr 20, 2021 · PreprintImmunology

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

K. Wu, A. P. Werner, J. I. Moliva, M. Koch, A. Choi, G. B. E. Stewart-Jones, H. Bennett, S. Boyoglu-Barnum, W. Shi, B. S. Graham, A. Carfi, K. S. Corbett, R. A. Seder, D. K. Edwards

This study evaluates the neutralizing antibody response of mRNA-1273 vaccine against SARS-CoV-2 variants B.1.1.7 and B.1.351 using pseudovirus neutralization assays.

bioRxiv · Jan 25, 2021 · PreprintImmunology

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness

K. S. Corbett, D. Edwards, S. R. Leist, O. M. Abiona, S. Boyoglu-Barnum, R. A. Gillespie, S. Himansu, A. Schafer, C. T. Ziwawo, A. T. DiPiazza, K. H. Dinnon, S. M. Elbashir, C. A. Shaw, A. Woods, E. J. Fritch, , Wang

This paper describes the development of an mRNA vaccine (mRNA-1273) against SARS-CoV-2, showing it induces neutralizing antibodies and CD8 T cell responses and protects mice from infection.

bioRxiv · Jun 11, 2020Immunology

Elicitation of broadly protective immunity to influenza by multivalent hemagglutinin nanoparticle vaccines

S. Boyoglu-Barnum, D. Ellis, R. A. Gillespie, G. B. Hutchinson, Y.-J. Park, S. M. Moin, O. Acton, R. Ravichandran, M. Murphy, D. Pettie, N. Matheson, L. Carter, A. Creanga, M. J. Watson, S. Kephart, , M. Kanekiyo

Nanoparticle immunogens with four seasonal influenza hemagglutinins elicit neutralizing antibodies against both the head and stem, providing broad protection against diverse influenza strains.

bioRxiv · May 30, 2020 · PreprintImmunology

Design of nanoparticulate group 2 influenza hemagglutinin stem antigens that activate unmutated ancestor B cell receptors of broadly neutralizing antibody lineages

K. S. Corbett, S. M. Moin, H. M. Yassine, A. Cagigi, M. Kanekiyo, S. Boyoglu-Barnum, S. I. Myers, Y. Tsybovsky, A. K. Wheatley, C. A. Schramm, R. A. Gillespie, W. Shi, L. Wang, Y. Zhang, S. F. Andrews, , J. C. Boyington

This study designs nanoparticle-based influenza HA stem antigens that activate unmutated B cell receptors of broadly neutralizing antibodies, potentially enabling cross-group immunity.

bioRxiv · Dec 17, 2018Immunology